Clinical Trials Logo

Dyspepsia clinical trials

View clinical trials related to Dyspepsia.

Filter by:

NCT ID: NCT00232024 Completed - Dyspepsia Clinical Trials

Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia

Start date: January 2004
Phase: Phase 3
Study type: Interventional

This study is being done to evaluate the safety, tolerability and satisfactory relief of dyspepsia symptoms in females excluding those with predominant stomach pain. Tegaserod will be evaluated at 6mg twice daily and placebo.

NCT ID: NCT00222131 Completed - Indigestion Clinical Trials

Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients

Start date: October 2003
Phase: Phase 2
Study type: Interventional

Inhibition of gastric acid is the key to satisfactory relief of symptoms with esomeprazole in NUD patients

NCT ID: NCT00220883 Completed - Clinical trials for Functional Dyspepsia

Electrogastrogram (EGG) Reproducibility Study: EEG Readings in Normal Subjects and Dyspeptic Patients

Start date: August 2005
Phase:
Study type: Observational

The primary objective of this study is to determine whether EGG readings obtained from both normal subjects and dyspeptic patients are reproducible from one EGG recording to another on a different day. The secondary objective of this study is to determine whether the EGG readings are analyzed and diagnosed consistently when reviewed and compared by multiple blinded readers when the same tracing is reviewed.

NCT ID: NCT00220844 Terminated - Dyspepsia Clinical Trials

Tricyclic Antidepressants (TCAs) on Gastric Emptying

Start date: September 2005
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effects of two tricyclic antidepressant agents (TCAs), amitriptyline and desipramine, on gastric emptying and gastric accommodation using a newly developed scintigraphic test that simultaneously measures both gastric emptying and gastric volume (accommodation). These two tricyclic antidepressant agents are commonly used at low doses to treat patients with refractory functional dyspepsia.

NCT ID: NCT00217347 Completed - Clinical trials for Gastroesophageal Reflux Disease

Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy

Start date: September 2005
Phase: N/A
Study type: Interventional

The exploration of evocative symptoms of esophageal reflux disease or dyspepsia is based on a relatively invasive endoscopic examination, often badly tolerated, and which, in France, is carried out in 50% of the cases under general anaesthesia. The development of a Capsule Endoscopy, of single use, of esophageal exploration (PILLCAM OESO), could allow a painless exploration of the oesophagus, without infectious risk.The aim of this study is to validate the information provided by the Esophageal Capsule Endoscopy compared to upper endoscopy in the screening of patients with gastroesophageal reflux disease or dyspepsia . For that these patients, after being informed and to have given their signed assent, will initially have an exploration by Esophageal Capsule Endoscopy and then, the very same day or within 3 days maximum, a upper endoscopy'. The information provided by the Esophageal Capsule Endoscopy then by the upper endoscopy will be analyzed by investigators different. This study should make it possible to evaluate the parameters of specificity, sensitivity and predictive values of Esophageal Capsule Endoscopy in this indication.

NCT ID: NCT00173953 Completed - Dyspepsia Clinical Trials

Lymphocytic Subsets and Cytokine Production With H. Pylori Infection

Start date: January 2001
Phase: N/A
Study type: Interventional

The aims of this study are 1) to determine the cytokines produced by both Th1 and Th2 subsets in gastric antral biopsy specimens from Taiwanese patients before and after anti H. pylori therapy; 2) to obtain a detailed phenotypic characterization and distribution pattern of mucosal lymphocytes in H. pylori-associated gastritis and to define possible contributing immune mechanisms responsible for the chronicity of the disease and its associated lesions.

NCT ID: NCT00171470 Completed - Dyspepsia Clinical Trials

The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.

Start date: April 2005
Phase: Phase 3
Study type: Interventional

Study to provide initial data to assess the safety and efficacy of tegaserod use in patients with dyspepsia that are being treated with proton pump inhibitors (PPI's) for heartburn.

NCT ID: NCT00171457 Completed - Dyspepsia Clinical Trials

The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia.

Start date: April 2005
Phase: Phase 3
Study type: Interventional

Investigate the role of tegaserod in modulating gastric sensitivity to mechanical distention of the stomach

NCT ID: NCT00164996 Completed - Dyspepsia Clinical Trials

Ultrathin Versus Conventional Esophagogastroduodenoscopy in Unsedated Patient With or Without Local Pharyngeal Anaesthesia

Start date: September 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate whether an ultrathin endoscope will improve a patient's tolerance during the procedure. In addition, this study will look at whether local pharyngeal anaesthesia is necessary during ultrathin endoscopy.

NCT ID: NCT00164775 Completed - Clinical trials for Functional Gastrointestinal Disorder

The Efficacy of Imipramine in Treatment of Refractory Functional Dyspepsia

Start date: June 2005
Phase: Phase 3
Study type: Interventional

The aim of this study is evaluate the efficacy of Imipramine, a tricyclic antidepressant, in treatment of functional dyspepsia. This is a double blind randomised placebo controlled trial in which consecutive patients with diagnosis of functional dyspepsia will be studied. After exclusion of organic cause of dyspepsia by endoscopy, these patients will be randomly assigned to either imipramine or placebo. All the patients will enter an additional 4 weeks of drug withdrawal phase after the initial 12 weeks of study drug treatment. They will be evaluated for treatment response, which is defined as satisfactory relief of dyspeptic symptoms at the end of 12-week treatment.